Structure-based screening of natural product libraries in search of potential antiviral drug-leads as first-line treatment to COVID-19 infection.

The study focuses on identifying and screening natural products (NPs) based on their structural similarities with chemical drugs followed by their possible use in first-line treatment to COVID-19 infection. In the present study, the in-house natural product libraries, consisting of 26,311 structures, were screened against potential targets of SARS-CoV-2 based on their structural similarities with the prescribed chemical drugs. The comparison was based on molecular properties, 2 and 3-dimensional structural similarities, activity cliffs, and core fragments of NPs with chemical drugs. The screened NPs were evaluated for their therapeutic effects based on their predicted in-silico pharmacokinetic and pharmacodynamics properties, binding interactions with the appropriate targets, and structural stability of the bound complex using molecular dynamics simulations. The study yielded NPs with significant structural similarities to synthetic drugs currently used to treat COVID-19 infections. The study proposes the probable biological action of the selected NPs as Anti-retroviral protease inhibitors, RNA-dependent RNA polymerase inhibitors, and viral entry inhibitors.

Introduction

Viral infections play an important role in human diseases, and their regular outbreaks repeatedly underlined the need for their prevention in safeguarding public health [1]. The recent outbreak of COVID-19 disease was declared a ‘public health emergency of international concern' by World Health Organization (WHO) in view of its severity [2]. The Coronavirus disease (COVID-19), previously known as ‘2019 novel coronavirus' or ‘2019-nCoV′, is an infectious disease caused by a newly discovered coronavirus; severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 [3]. The SARS-CoV-2 is a member of the Coronavirinae family belonging to the Betacorona genus [4]. Structurally it is spherical or pleomorphic in shape, with a diameter of about 60–140 nm. All ages are susceptible to COVID-19 infection, and its clinical manifestations range from asymptomatic to mild to severe and even to death depending on the underlying health conditions of individuals [5,6]. The most commonly reported symptoms are fever, chills, headache, body aches, dry cough, fatigue, pneumonia, and complicated dyspnea. The virus transmits from person to person via the nasal, oral, eye, and mucosal secretions of the infected patient and direct transmission through the inhalation of droplets released during the patient's cough or sneeze [7,8].

Fig. 1 describes some of the most widely used vaccines currently developed against COVID-19. The other potential treatment strategies include inhibition of RNA-Dependent RNA Polymerase activity, viral protease inhibition, viral entry inhibition, immune modulation, monoclonal antibodies, janus kinase inhibitors, nutritional supplements, and conventional plasma therapy (Table S1) [9]. The developmental status of different antiviral drugs to treat COVID-19 conditions is shown in Fig. 2 .

Fig. 1

Most widely used vaccines currently developed against COVID-19.

Fig. 2

The broad-spectrum antiviral drugs currently being investigated to treat the COVID-19 condition.

Natural products and traditional medicines have been serving as the greatest source for modern drug discovery. Their derivatives have been recognized for many years as the source of therapeutic potential and structural diversity. There are over 200,000 compounds reported in the scientific literature. NPs are more often structurally complex, with well-organized structure and steric properties offering efficacy, efficiency, and selectivity of molecular targets [10]. However, their utilization on many health conditions is well documented; it is in the hands of existing traditional practitioners and herbologists to define their applications for newly emerging diseases. The biological activities reported from different plant extracts often narrow down to pre-reported molecules rather than novel compounds [11], creating a real challenge to medicinal chemists. In this avenue, the search for new therapeutic molecules is the need of the hour to combat new health challenges.

The biological activity of any molecule is attributed to its structural arrangements. If two molecules have a similar structure, they will probably have a similar biological effect [[12], [13], [14]] (Fig. 3 ). The computational chemists successfully exploit this principle for the construction of diverse compound libraries and select compounds for high-throughput screening experiments [12]. Computational advancements with the introduction of parallel processing clusters, cloud-based computing, and highly effective graphical processing units (GPUs), tremendous success has been achieved in the field of modern drug discovery [15]. The knowledge of natural products and ligands, earlier used as starting points for drug discovery, has greatly influenced computational biology techniques [16]. These advancements have been speeded up by the creation of new algorithms for more accurate predictions, simulations, and interpretations [[17], [18], [19], [20], [21], [22]]. The extensive molecular dynamics (MD) simulations can provide insights into the host-virus interactions, disease spread, and possible regulative/preventive mechanisms [23]. In this avenue, the present study proceeds to exploit these developments to identify natural products as potential drug leads targeting some of the most widely used antiviral drugs currently being used against SARS-CoV-2. The identified molecules envisage to be potential drug leads and, with critical screening and trials, could be used in the first-line treatment for COVID-19 infections.

Fig. 3

A comparison describing the structural similarities with variations highlighted inside the ellipse between thymidine, a naturally occurring nucleotide base, and zidovudine, a synthetic drug used to treat HIV patients. Structurally both the molecules share >93% identity.

Material and method

Dataset collection and library construction

An in-house natural product library consisting of 26,311 natural product structures was constructed using natural products information from different databases like Dr. Duke's database (https://phytochem.nal.usda.gov/phytochem/search) [24], Phytochemical Interactions Database (http://www.genome.jp/db/pcidb), and Natural product activity and species source database (NPASS) (http://bidd.group/NPASS/index.php) [25]. The plant's secondary metabolites are classified into various classes according to their chemical structures [26]. Their classification as phenolics, alkaloids, Flavonoids, Tannins, Coumarins, terpenes, Lignans, etc., with polyphenols further classified into flavans, flavones, and isoflavonoids are of particular interest to medicinal chemists due to their diverse therapeutic effects [27,28]. Therefore, the polyphenols from the natural product library were further categorized as flavans (339), flavones (193), and isoflavonoids (457), and the rest of the molecules as a general group. The broad-spectrum antiviral drugs currently under investigation to treat COVID-19 conditions were collected from the drugvirus.info server (https://drugvirus.info). For comparison, the small molecule synthetic drugs were categorized into molecules present in Pubchem COVID-19 portal (306) [29] (https://pubchem.ncbi.nlm.nih.gov/#query=covid-19), and molecules present at different stages of clinical trials (138) (As of 31st August 2020) based on the available information from ClinicalTrials.gov database [30] (https://www.clinicaltrials.gov/ct2/home). Further, the study was extended to compare the most promising investigational drugs like Remdesivir, Arbidol, Lopinavir, and Ritonavir. The top 10 structures with structurally most similar to investigational drugs were selected for in-silico PK/PD analysis and HTVS (high throughput virtual screening) studies.

Structure-based screening of natural products

The non-redundant natural product libraries were compared against chemical drugs currently under prescription/study to treat COVID-19 infection. The comparison was based on 2 and 3-dimensional structural similarities, activity cliffs (ACs), and core fragments (CFs). The structural similarities were assessed based on the number of fragments that both molecules have to the number of fragments found in any two structures [31]. The structural scaffolds (SSs) were analyzed based on plane ring system to determine the sub-structures. ACs, CFs, and SSs were determined employing Osiris DataWarrior V.4.4.3 software [31].

Pharmacophore based comparison of natural products with their synthetic drugs counterparts:

To find structurally similar compounds rather than compounds sharing a common sub-structure, core fragment-based SAR analysis was performed by considering the most central ring structure. The similarities between the fragments were assessed based on the number of fragments that both molecules have in common, divided by the number of fragments being found in any of the two structures [[31], [32], [33]]. The structures were further analyzed for structural scaffolds based on plane ring system to determine the substructures and to define the similarity cut-off during the structure comparison. The molecular properties, activity cliff, core fragments, and structural scaffolds were predicted using Osiris DataWarrior V.4.4.3 software [31,34].

Similarity score cut-off limit:

Natural products exist in many of their stable analogs forms in nature. Even with minor structural variations, the analogous forms of natural products can exert unique biological effects [35]. Therefore, there was a need to set an appropriate limit to filter natural products and their analogous structures. Due to their complex structures, at higher cut-off limits, such derivatives are expected to exclude, while at lower cut-off limits, the analogous structures become inclusive (Table S2). By considering such variations, a similarity cut-off limit of 60% was fixed for the comparison [34].

Molecular properties based PK/PD analysis

Natural products are the major source of oral drugs ‘beyond Lipinski's rule of five' [[36], [37], [38]]. The drug-likeness assessment, pharmacokinetic (PK), and pharmacodynamics (PD) of NPs were determined based on their molecular properties like molecular weight, cLogP, hydrogen atom donors, hydrogen atom acceptors, and rotatable hydrogen bonds. These properties are used as filtering parameters to estimate the oral bioavailability, solubility, and permeability of new drug candidates [36,38,39]. The natural products obtained from structural comparison were considered as hits for in-silico PK/PD assessment to analyze mutagenicity, tumorigenicity, reproductive effectiveness, irritant properties, and drug likeliness. Molecular properties were predicted using Osiris Data warrior V.4.4.3 software [31]. The admetSAR server [40] was used to predict solubility, permeability, GPCR ligand, ion channel modulator, protease inhibitor, kinase inhibitor, enzyme inhibitor, nuclear receptor inhibitor, aqueous solubility, TPSA (Topological polar surface area), blood-brain barrier penetration, human intestinal absorption, Caco-2 permeability, AMES toxicity, carcinogenicity and acute oral toxicity of the selected molecules [38,21].

Molecular interactions studies using automated docking

Automated docking was performed to deduce the binding interactions of selected natural products with appropriate target proteins. Broyden-Fletcher-Goldfarb-Shanno algorithm implemented in the AutoDockVina was employed to study proper binding modes of the selected natural products in different conformations [42]. The antiviral drugs currently being prescribed for COVID-19 first-line treatment were retrieved from the drugvirus.info server, and their action mechanisms were studied using the Inxight: Drugs database (https://drugs.ncats.io/) (Table S1).

Based on the action mechanism of the standard drugs, HIV-1 protease I50V isolate, influenza virus hemagglutinin, SARS-CoV NSP12 polymerase, and HIV-1 protease A02 isolate were selected for the docking studies. The protein structures were retrieved from protein databank (https://www.rcsb.org/) and were prepared for docking studies. For each target, residues forming the binding site were retrieved using the PDBsum server. The antiviral drug; Lopinavir and its related natural products were docked against anti-retroviral protease inhibitor (I50V isolate) (PDB ID 3OXV), Ritonavir and its related natural products were docked against anti-retroviral protease inhibitor (A02 isolate) (PDB ID 4NJV), Remdesivir, and its related natural products were docked against anti-retroviral protease inhibitor (PDB ID 7BV2), and Arbidol and its related natural products were docked against anti-retroviral protease inhibitor (PDB ID 5T6S). During molecular docking, the energy range was set to 3, exhaustiveness to 8, and the number of modes to 9. For the ligand molecules, all the torsions were allowed to rotate during docking. The in-silico studies were performed on a local machine equipped with AMD Ryzen 5 six-core 3.4 GHz processor, 8 GB graphics, and 16 GB RAM with Microsoft Windows 10 and Ubuntu 16.04 LTS dual boot operating systems.

Molecular dynamic simulations to predict the protein structural stability

The structural stability of the free and bound targets was assessed using MD simulations run for a time scale of 20 ns [43,44] by employing the GROMOS96 54a7 [45] force field implemented in the GROMACS-2018 package [46]. A periodic cubic solvated box was created around the target proteins with at least 10 Å distance from the edge of the box and solvated using the simple point charge (SPC) model [47] and neutralized using sodium or chloride ions. The energy minimization was done using the steepest descent method. The system was equilibrated with a temperature coupling at 300K using V-rescale thermostat [48] in NVT ensemble and pressure coupling at 105 Pa using Parrinello-Rahman barostat [49] in NPT ensemble for a period of 500 ps. Bond parameters were adjusted using the LINCS algorithm [50], and the particle mesh Ewald method (PME) [51] was used to evaluate electrostatic interactions. A cut-off at 1.0 nm was set for the long-distance interactions as MD simulation accurately predicts properties of the system for a larger cut-off distance [52]. The final MD trajectories were prepared for a time scale of 20ns at a time step of 2fs with trajectory coordinates updated at 10ps intervals. The final trajectories were analyzed using gmx energy, gmx rms, gmx rmsf, gmx gyrate, gmx do_dssp, and gmx sasa modules of GROMACS along with interaction energies in terms of electrostatic and van der Waals energy between the ligand and the macromolecule.

Biding free energy calculations using g_mmpbsa

For Molecular mechanics/Poisson-Boltzmann surface area (MMPBSA) calculations, trajectory files were created from the final production MD trajectory with coordinates updated every 200ps. The g_mmpbsa package was used for binding energy calculations [53]. The g_mmpbsa package uses the following equation to calculate the binding energy of the protein-ligand complex;

The ‘G' term can be further decomposed into the following componentsWhere,

G Complex = total free energy of the binding complex,

G Protein and G Ligand = total free energies of protein and ligand, respectively.

EMM = vacuum potential energy; G Solvation = free energy of solvation

Results

The natural product library consisting of 26,311 structures was screened against the local Pubchem COVID-19 library of COVID-19 prescribed drugs and COVID-19 clinical trials drug library. Among the total number of molecules screened, 17,798 natural product structures were found to have more than 60% structural similarities against the Pubchem COVID-19 library entries, of which 41 molecules were flavans, 41 were flavones, and 272 were isoflavonoids. The comparison against clinical trials drug library yielded 14,689 natural products with more than 60% structure similarity consisting of 30 flavans, 18 flavones, and 78 isoflavonoids. The study was extended to compare the complete natural product library against the most promising investigational drugs, viz. Remdesivir, Arbidol, Lopinavir, and Ritonavir molecules. This comparison yielded a total of 35 natural product structures with more than 60% structural similarity. The natural products with structural similarities to respective investigational drugs are detailed in Table 1 .

Table 1

Natural products (with NPASS accession) that are structurally similar to prescribed COVID-19 drugs and their similarity score.

Synthetic drug and the identified NPs	Molecular structure	Similarity score
Remdesivir	Image 1
12,28-Oxa-8-Hydroxy-Manzamine A (NPC471891)	Image 2	0.7676
Marineosin A (NPC141377)	Image 3	0.7558
Bis(Gorgiacerol)Amine(NPC128683)	Image 4	0.8107
Methylstemofoline (NPC477986)	Image 5	0.7645
Chetracin B (NPC470488)	Image 6	0.7877
Oxyprotostemonine (NPC173173)	Image 7	0.7644
Stemocurtisine (NPC43648)	Image 8	0.7569
Munroniamide (NPC176245)	Image 9	0.7705
Alstolobine A (NPC277350)	Image 10	0.7598
Discorhabdin H (NPC477417)	Image 11	0.7665
Arbidol	Image 12
Phellibaumin A (NPC29411)	Image 13	0.6838
Difloxacin (NPC318183)	Image 14	0.7363
Lamellarin D (NPC129897)	Image 15	0.7175
Lamellarin Gamma Acetate (NPC476995)	Image 16	0.6682
Hydroxy-6-Methylpyran-2-One Derivative (NPC470989)	Image 17	0.6822
Cyathuscavin C (NPC474779)	Image 18	0.7363
Cyathusal B (NPC317781)	Image 19	0.7135
Clausarin (NPC83535)	Image 20	0.6770
Cyathuscavin B (NPC474763)	Image 21	0.7135
Pulvinatal (NPC327652)	Image 22	0.7010
Lopinavir	Image 23
Hexahydrodipyrrolo trione derivative (NPC122886)	Image 24	0.7458
Beauvericin (NPC89923)	Image 25	0.7478
Chaetocin (NPC128582)	Image 26	0.7615
Mollenine A (NPC285622)	Image 27	0.7462
Chetracin B (NPC470488)	Image 28	0.7877
Beauvericin H1 (NPC157311)	Image 29	0.7549
Dragonamide A (NPC222466)	Image 30	0.7703
Chetracin D (NPC470491)	Image 31	0.7892
Dimethyl-3-Oxodecanamide derivative (NPC324081)	Image 32	0.7569
Symplocamide A (NPC473450)	Image 33	0.7481
Ritonavir	Image 34
Bionectin B (NPC475859)	Image 35	0.7146
Luteoalbusin A (NPC470731)	Image 36	0.6906
Bionectin A (NPC165743)	Image 37	0.7122
Oidioperazine A (NPC297642)	Image 38	0.7153
Holstiine (NPC11149)	Image 39	0.6876
Chetracin B (NPC470488)	Image 40	0.7142
Mollenine A (NPC285622)	Image 41	0.6796
Methaniminium derivative (NPC194699)	Image 42	0.7274
Verticillin E (NPC191817)	Image 43	0.7181
Chaetocin (NPC128582)	Image 44	0.6888

Molecular properties and Pharmacokinetics prediction of natural products were predicted using Osiris data warrior software and the admetSAR server. The drug-likeness estimated based on the molecular properties of the selected structures indicated that out of 35 molecules, 23 molecules with positive scores indicated their potential drug-like effects (Table 2 A). Gastrointestinal (GI) absorption is an important parameter to screen orally administered drugs. A positive value shown in Table 2A for gastrointestinal (GI) absorption suggests a high probability of success for absorption into the intestinal tract [54]. While the blood-brain barrier (BBB) penetration indicates the potential of a drug to cross into the brain, it can bind to specific receptors and activate specific signaling pathways. Therefore, the prediction of BBB penetration is crucial in the drug development pipeline [55]. In the present study, 33 molecules were found to penetrate the human intestine barrier, 17 molecules penetrating the blood-brain barrier. None of them was the substrate for Cytochromes P450 group of isozymes that regulates drug metabolism, indicating a high possibility of their bioavailability (Table 2A). Further, out of 35 molecules, 34 were predicted to be non-mutagenic, non-tumorigenic, and non-irritant, with 10 molecules predicted to have reproductive effects (Table 2 B). Among the 35 structures, 29 compounds were non-AMES toxic, 34 non-carcinogens, and 34 were not readily biodegradable.

Table 2A

) Molecular properties and Pharmacokinetics prediction of natural products filtered in for screening against COVID-19 condition.

Identified NPs	Bioavailability and Druglikeness								In silico Pharmacokinetics
	cLogP	Mol. wt	H-Acceptors	H-Donors	Rotatable Bonds	Total Surface Area	Polar Surface Area	Druglikeness	Human intestinal absorption	Caco-2 permeability	Blood-brain barrier	CYP2D6 substrate
12,28-Oxa-8-Hydroxy-Manzamine A	5.2547	562.755	6	2	1	414.34	60.33	−2.227	0.696+	0.541-	0.800+	0.671-
Alstolobine A	2.4707	398.457	7	1	6	297.41	80.86	−8.1671	0.988+	0.566-	0.896+	0.816-
Beauvericin	5.2239	783.96	12	0	9	610.8	139.83	4.3764	0.991+	0.661+	0.678+	0.825-
Beauvericin H1	5.3247	801.95	12	0	9	617.15	139.83	3.0364	0.990+	0.599+	0.786+	0.829-
Bionectin A	2.9631	450.542	7	3	1	282.66	139.27	5.5488	0.889+	0.508+	0.608+	0.831-
Bionectin B	2.6488	494.595	8	4	2	311.68	159.5	5.0182	0.900-	0.525-	0.832-	0.838-
Bis(Gorgiacerol)Amine	5.4399	757.83	13	3	10	560.06	183.97	−19.005	0.965-	0.616-	0.932-	0.848-
Chaetocin	2.7962	696.852	12	4	3	409.82	246.96	5.8356	0.900+	0.626-	0.661-	0.801-
Chetracin B	1.092	760.916	14	6	3	437.49	312.72	5.4873	0.885+	0.574-	0.816-	0.805-
Chetracin D	0.3976	788.99	14	6	7	496.04	287.42	5.6124	0.922+	0.589-	0.869-	0.805-
Clausarin	5.9768	380.482	4	1	4	295.44	55.76	−5.9217	0.975+	0.840-	0.825+	0.867-
Cyathusal B	0.5256	346.29	8	3	3	243.75	122.52	−4.326	0.915+	0.592+	0.767-	0.909-
Cyathuscavin B	0.5053	376.316	9	3	4	264.22	131.75	−4.7328	0.878+	0.627+	0.775-	0.894-
Cyathuscavin C	0.0774	362.289	9	4	3	248.31	142.75	−2.2479	0.868+	0.592+	0.767-	0.909-
Difloxacin	1.251	399.396	6	1	3	283.48	64.09	5.1997	0.985+	0.879+	0.968-	0.911-
Discorhabdin H	−10.123	762.664	10	3	5	337.61	198.19	2.7192	0.734+	0.603-	0.903-	0.795-
Dragonamide A	3.7111	653.905	10	2	18	539.59	125.32	−3.0172	0.969+	0.543-	0.628-	0.783-
Hexahydrodipyrrolo trione derivative	0.2123	427.456	9	3	2	288.36	119.41	6.7335	0.946+	0.615-	0.978-	0.802-
Holstiine	1.5964	382.458	6	1	0	270.15	70.08	5.6428	0.972+	0.631+	0.567+	0.784-
Hydroxy-6-Methylpyran-2-One Derivative	5.228	500.586	8	4	11	387.58	141.36	−13.889	0.984+	0.563+	0.660-	0.866-
Lamellarin D	4.3105	499.474	9	3	4	352.71	119.09	1.8379	0.983+	0.604+	0.606+	0.448-
Lamellarin Gamma Acetate	5.3	573.596	10	1	8	423.68	106.84	2.3739	0.987+	0.683+	0.747+	0.628-
Luteoalbusin A	3.1416	464.569	7	3	2	295.59	139.27	5.9847	0.890+	0.581-	0.575+	0.812-
Marineosin A	4.6896	409.572	5	2	2	323.4	62.4	−2.232	0.986+	0.638-	0.824+	0.764-
Methaniminium derivative	−0.4649	910.463	21	10	14	679.31	329.1	6.1103	0.795+	0.647-	0.976-	0.831-
Methylstemofoline	0.9975	345.394	6	0	1	220.03	57.23	4.0559	0.922+	0.670+	0.679+	0.741-
Mollenine A	3.3511	368.475	5	1	4	275.46	58.64	3.6919	0.980+	0.516-	0.608+	0.824-
Munroniamide	−0.4894	597.663	12	2	7	419.88	166.86	−8.9989	0.940+	0.628-	0.500+	0.808-
Oidioperazine A	1.9865	538.647	9	3	4	357.08	167.78	6.2082	0.843+	0.510-	0.807-	0.506-
Oxyprotostemonine	1.004	431.483	8	0	2	289.89	83.53	2.3627	0.890+	0.648+	0.549+	0.803-
Phellibaumin A	2.8483	352.297	7	4	2	248.17	120.36	0.0022	0.952+	0.828-	0.725+	0.905-
Pulvinatal	0.9535	360.317	8	2	4	259.66	111.52	−6.9354	0.919+	0.627+	0.775-	0.894-
Stemocurtisine	1.4247	347.41	6	0	1	239.64	57.23	2.9196	0.922+	0.668+	0.758+	0.744-
Symplocamide A	0.6976	1052.03	23	11	18	763.41	359.52	1.3524	0.915+	0.634-	0.959-	0.830-
Verticillin E	1.7482	752.872	14	4	3	439.8	281.1	4.5639	0.895+	0.536-	0.836-	0.825-

Table 2B

) In-silico Pharmacodynamics prediction of natural products selected for screening against COVID-19 condition.

Identified NPs	Mutagenic	Tumorigenic	Reproductive effective	Ocular irritancy	Aerobic biodegradibility	Ames tooxicity score	Carcinogen
12,28-Oxa-8-Hydroxy-Manzamine A	NONE	NONE	NONE	0.946-	1.00-	0.707-	0.607-
Alstolobine A	NONE	HIGH	NONE	0.979-	1.00-	0.714-	0.573-
Beauvericin	NONE	NONE	NONE	0.925-	0.912-	0.772-	0.622-
Beauvericin H1	NONE	NONE	NONE	0.922-	0.996-	0.776-	0.536-
Bionectin A	NONE	NONE	NONE	0.972-	0.986-	0.733-	0.609-
Bionectin B	NONE	NONE	NONE	0.965-	0.988-	0.870-	0.611-
Bis(Gorgiacerol)Amine	NONE	NONE	HIGH	0.901-	0.623-	0.573-	0.487-
Chaetocin	NONE	NONE	NONE	0.918-	0.994-	0.645-	0.623-
Chetracin B	NONE	NONE	NONE	0.911-	0.973-	0.679-	0.644-
Chetracin D	NONE	NONE	NONE	0.904-	0.996-	0.678-	0.627-
Clausarin	NONE	NONE	HIGH	0.607+	0.993-	0.506-	0.472-
Cyathusal B	NONE	NONE	HIGH	0.561-	0.937-	0.707+	0.465-
Cyathuscavin B	NONE	NONE	HIGH	0.590-	0.966-	0.712+	0.515+
Cyathuscavin C	NONE	NONE	HIGH	0.574-	0.937-	0.707+	0.465-
Difloxacin	NONE	NONE	NONE	0.949-	1.00-	0.885+	0.610-
Discorhabdin H	NONE	NONE	NONE	0.960-	1.00-	0.593-	0.532-
Dragonamide A	NONE	NONE	NONE	0.922-	1.00-	0.812-	0.678-
Hexahydrodipyrrolo trione derivative	NONE	NONE	NONE	0.927-	1.00-	0.658-	0.597-
Holstiine	NONE	NONE	NONE	0.986-	0.951-	0.572-	0.501-
Hydroxy-6-Methylpyran-2-One Derivative	NONE	NONE	NONE	0.732-	0.500+	0.815-	0.723-
Lamellarin D	NONE	NONE	HIGH	0.833-	0.993-	0.586-	0.389-
Lamellarin Gamma Acetate	NONE	NONE	HIGH	0.989-	0.995-	0.880-	0.599-
Luteoalbusin A	NONE	NONE	NONE	0.986-	0.987-	0.670-	0.630-
Marineosin A	NONE	NONE	NONE	0.972-	1.00-	0.655-	0.651-
Methaniminium derivative	NONE	NONE	NONE	0.905-	0.962-	0.615-	0.570-
Methylstemofoline	NONE	NONE	NONE	0.891-	1.00-	0.755-	0.470-
Mollenine A	NONE	NONE	NONE	0.986-	0.997-	0.572-	0.528-
Munroniamide	LOW	HIGH	LOW	0.978-	1.00-	0.512-	0.562-
Oidioperazine A	NONE	NONE	NONE	0.987-	0.997-	0.670-	0.606-
Oxyprotostemonine	NONE	NONE	NONE	0.943-	0.994-	0.681-	0.440-
Phellibaumin A	HIGH	NONE	HIGH	0.528-	0.911-	0.550+	0.419-
Pulvinatal	NONE	NONE	HIGH	0.547-	0.966-	0.712+	0.515+
Stemocurtisine	NONE	NONE	NONE	0.914-	0.995-	0.781-	0.420-
Symplocamide A	NONE	NONE	NONE	0.901-	0.945-	0.644-	0.594-
Verticillin E	NONE	NONE	HIGH	0.900-	0.986-	0.763-	0.610-

The in-silico molecular interaction studies were used to predict the most effective natural product drug to bind to the appropriate target involved in the regulation of virus entry, replication, assembly, and release, as well as host-specific interactions. In the present study, the docking studies were carried out for synthetic antiviral agents as well as their structurally similar natural products against different targets proteins of SARS-CoV-2 to deduce the structural insight of molecular interactions. The study yielded natural products being effectively bound to their respective targets (Table 3 ). The results were expressed in terms of docking energy (kcal/mol). Many selected natural products have displayed docking energies lower than their structurally similar standard drug counterparts. The natural products similar to Remdesivir interact with SARS-CoV NSP12 polymerase with docking energies comparably lower than the standard drug. The natural products tested as influenza virus hemagglutinin inhibitors are also bound to the target with docking energies lower than the standard drug arbidol. The binding interactions of natural products tested as viral protease inhibitors were compared with standard drugs Lopinavir and Ritonavir. The effectiveness of these binding of natural products with the highest interaction energy in each group was selected for protein stability assessment using molecular dynamics simulations (Fig. 4 ).

Table 3

Molecular interactions between the selected natural products with targets of their structurally similar chemical drugs expressed as docking energies along with their structure similarity score. The table also details the number of hydrogen bonds formed between the Natural product and the amino acid residues from the target molecule.

Target protein	Synthetic drug and the identified NPs	Docking Energya	H-bonds	Receptor residues involved in H-bond formation
SARS-CoV NSP12 POLYMERASE	Remdesivir	−7.2	03	ILE23, LEU126, GLY48
	12,28-Oxa-8-Hydroxy-Manzamine A	−10.4	02	GLY130, ALA38
	Marineosin A	−7.9	00	–
	Bis(Gorgiacerol)Amine	−7.8	02	ILE23, GLY130
	Methylstemofoline	−7.7	02	SER128, ALA129
	Chetracin B	−7.5	01	PHE156
	Oxyprotostemonine	−7.5	02	SER128, ALA129
	Stemocurtisine	−7.5	01	GLY48
	Munroniamide	−6.9	05	VAL49, ILE131, GLY48, GLY130, LEU126
	Alstolobine A	−6.8	03	PHE156, ASP157, ALA154
	Discorhabdin H	−6.7	02	GLY48, ASP22
INFLUENZA VIRUS HEMAGGLUTININ	Arbidol	−7.1	01	GLU64
	Phellibaumin A	−9.4	04	ASP280, SER290, LYS58, ILE288
	Difloxacin	−8.4	03	LYS58, LEU292, PRO293
	Lamellarin D	−8.4	02	LYS58, CYS305
	Lamellarin Gamma Acetate	−7.8	01	GLU57
	Hydroxy-6-Methylpyran-2-One Derivative	−7.6	03	THR59, GLU57, THR59
	Cyathuscavin C	−7.5	02	GLU57, PRO306
	Cyathusal B	−7.4	02	GLU57, PRO306
	Clausarin	−7.3	02	GLU64, ARG85
	Cyathuscavin B	−7.3	00	–
	Pulvinatal	−7.3	01	THR59
HIV-1 PROTEASE I50V ISOLATE	Lopinavir	−6.5	03	GLY49, GLY51, GLY52
	Hexahydrodipyrrolo trione derivative	−8.4	03	PRO81, ASP25, GLY48
	Beauvericin	−7.2	01	GLY49
	Chaetocin	−7.1	06	THR74, ASN88, GLN92, ASP30, ILE72, GLY73
	Mollenine A	−7.1	00	–
	Chetracin B	−6.9	00	–
	Beauvericin H1	−6.6		VAL50, GLY51, THR80
	Dragonamide A	−6.3	02	ASP30, VAL50
	Chetracin D	−6.2	04	THR74, ARG87, ASP29, GLY73
	Dimethyl-3-Oxodecanamide derivative	−5.6	03	VAL50, GLY51, PHE53
	Symplocamide A	−4.6	00	–
HIV-1 PROTEASE A02 ISOLATE	Ritonavir	−7.7	04	ASP29, ASP30, GLY48, GLY49
	Bionectin B	−8.1	03	ILE50, THR82, GLY51
	Luteoalbusin A	−8.0	04	GLY51, GLY52, PRO81, PRO79
	Bionectin A	−7.7	02	THR96, ASN98
	Oidioperazine A	−7.7	02	ILE50, ASP25
	Holstiine	−7.1	00	–
	Chetracin B	−7.0	02	ARG87, LUE97
	Mollenine A	−6.9	00	–
	Methaniminium derivative	−6.6	01	PRO81
	Verticillin E	−6.6	02	THR74, ASN88
	Chaetocin	−6.4	02	ARG08, THR26

kcal/mol.

Fig. 4

Docking interaction between Remdesivir (a), and 12,28-Oxa-8-Hydroxy-Manzamine A (b) with SARS-CoV NSP12 polymerase, Arbidol (c), and Phellibaumin A (d) with influenza virus hemagglutinin, Lopinavir (e), and Hexahydrodipyrrolo trione derivative (f) with HIV-1 protease I50V isolate and Ritonavir (g), and Bionectin B (h) with HIV-1 protease A02 isolate.

In the present study, united-atom MD simulations were performed to confirm the accuracy of binding resulting from docking studies [56]. The result of the MD simulation displayed the conformational changes acquired by different target proteins of SARS-CoV-2 upon binding and inferred the structural insight on molecular stability (Fig. 5 ).

Fig. 5

RMSD (a–d), RMSF (e–h), Rg (i–l) and SASA (m–p) plots obtained from MD trajectories analysis of native, Natural product bound, and chemical drug bound structure of SARS-CoV NSP12 polymerase, influenza virus hemagglutinin, and HIV-1 protease of I50V isolate and A02 isolate.

The RMSD analysis was done to understand the deviation of Cα atoms of the protein from its backbone, and RMSF analysis was done to study the fluctuations associated with the amino acid residues of the protein during the simulation. The average RMS deviations and RMS fluctuations were calculated from the MD trajectories of natural product, and synthetic drug bound HIV-1 protease (I50V isolate), Influenza virus hemagglutinin, SARS-CoV NSP 12 polymerase, and HIV-1 protease (A02 isolate) and were compared with their respective unbound structures (Table 4 ). The RMSD plots indicate that Remdesivir bound SARS CoV NSP 12 polymerase (Fig. 4a) and Arbidol bound Influenza virus hemagglutinin (Fig. 4b) displayed lesser deviations than their structurally similar natural products, Hydroxy Manzamin A and Phellibaurin_A bound structures. However, the macromolecular structures HIV-1 protease (I50V isolate) (Fig. 4c) and HIV-1 protease (A02 isolate) (Fig. 4d) displayed lesser RMS deviations upon binding with respective natural products compared to their synthetic drug counterparts. It can also be seen from these plots that the deviations in the macromolecular structures are relatively low after 5ns in both conditions. From the RMSF plots (Fig. 4e–h), it can be inferred that, though the residues displayed minor fluctuations at certain positions, all proteins were able to retain their secondary structure's packability. This was inferred based on the Rg plots (Fig. 5i-l), where the structures were found to be very tightly packed, as the secondary structure elements like α-helix, β-sheet, and turn were remodeled at each time step of the MD simulation. The SASA plots (Fig. 5m–p) also supported these findings.

Table 4

Calculated MD parameters for native and ligand-bound SARS CoV2 drug targets obtained from the MD simulation along with binding energies and the contributing energy terms of the prescribed drugs and their most similar natural product calculated using g_mmpbsa module.

		SARS-CoV NSP12 POLYMERASE			INFLUENZA VIRUS HEMAGGLUTININ			HIV-1 PROTEASE I50V ISOLATE			HIV-1 PROTEASE A02 ISOLATE
Gromacs Modules		Native Protein	Remdesivir	12,28-Oxa-8-Hydroxy-Manzamine A	Native Protein	Arbidol	Phellibaumin A	Native Protein	Lopinavir	Hexahydrodipyrrolo trione derivative	Native Protein	Ritonavir	Bionectin B
	Potential Energy (x 10−6)	−0.638	−0.638	−0.637	−4.605	−4.604	−4.604	−0.436	−0.434	−0.436	−0.519	−0.518	−0.518
	RMSD (nm)	0.213	0.195	0.186	0.481	0.429	0.549	0.247	0.270	0.254	0.265	0.447	0.287
	RMSF (nm)	0.105	0.055	0.099	0.176	0.216	0.231	0.130	0.141	0.130	0.140	0.144	0.139
	Rg (nm)	1.558	1.523	1.524	2.802	2.835	2.763	1.316	1.307	1.342	1.343	1.488	1.352
	SASA (nm2)	92.95	85.00	87.13	175.24	176.47	177.43	59.57	60.05	60.92	64.83	71.84	64.44
	Secondary Structure	210.49	221.97	219.29	283.92	295.63	285.29	119.47	112.07	118.78	117.81	117.54	120.51
	Coul-SRa	–	−47.22	−3.84	–	−9.45	−65.80	–	−40.29	−30.24	–	−83.47	−66.90
	LJ-SRa	–	−92.72	−64.15	–	−109.61	−114.98	–	−113.62	−109.54	–	−326.78	−160.13
MMPBSA Module	Binding Energya	–	−63.68	−57.17	–	−104.39	−60.86	–	−77.59	−93.53	–	−180.45	−161.08
	SASA Energya	–	−19.36	−8.68	–	−14.03	−13.62	–	−14.11	−13.84	–	−34.91	−16.52
	Polar Solvation Energya	–	146.39	35.27	–	43.27	132.86	–	97.20	67.11	–	179.49	73.50
	Electrostatic Energya	–	−36.09	−3.27	–	−6.71	−51.28	–	−29.45	−17.77	–	−49.11	−32.73
	van der Waals Energya	–	−154.62	−80.48	–	−126.92	−128.81	–	−131.22	−129.03	–	−375.91	−185.33

kJ/mol.

The binding free energy calculations performed using the g_mmpba module displayed better binding of natural products with their respective target proteins. The binding free energies of natural products, 12,28-Oxa-8-Hydroxy-Manzamine A (−57.17 kJ/mol), Phellibaumin A (−60.86 kJ/mol), and Bionectin B (−161.08 kJ/mol) were found to be encouraging in deducing their interactions with their respective targets. However, their structurally similar synthetic drug counterparts viz. Remdesivir (−63.68 kJ/mol), Arbidol (−104.39 kJ/mol), and Ritonavir (−180.45 kJ/mol) displayed higher binding free energies towards their respective targets. Nevertheless, the binding free energy of the natural product Hexahydrodipyrrolo trione derivative (−93.53 kJ/mol) was found to be higher than its structurally similar standard drug counterparts; Lopinavir (−77.59 kJ/mol). The associated terms for binding free energy calculations along with the calculated MD parameters for unbound and ligand-bound targets detailing RMSD, RMSF, Rg, SASA, Secondary structure, Coul-SR energy, and LJ-SR energy are detailed in Table 4.

Discussion

Viral infections have always created challenges in human healthcare research. Identifying efficacious and cost-effective antiviral drugs in the absence of potential vaccines or standard therapies thus holds utmost importance. Due to the advancements in virology, molecular biology, and computational biology, we can now decipher the pathophysiology of many viral diseases, including COVID-19 infection [57]. Natural products have been playing an important role as complementary medicine to combat viral infections, and herbal medicines have been an excellent source for modern drug research programs for a long time [58]. Their origin, availability, safety, and cost-effectiveness make them a reliable choice alongside modern medicine [59].

With the advancements in computational techniques, new strategies have been designed to predict the interactions of potential human target proteins with specific viral strains [60]. These models rely on the available interaction information to predict the novel host-virus interactions. These predictions have been reliable in the past in understanding the infection mechanism of SARS-CoV [61], MERS-CoV [61], Ebola virus [62], and Zika virus [63]. However, these computational methods play a significant role in modern drug research; the experimental verifications of virus-host interactions are needed to substantiate the potential interactions [[64], [65], [66]]. Along with this, the availability of verified interactions and relevant information is a prerequisite for computational drug discovery methods. Most of the chemical structure search and identification methods today rely on the conventional string search to modern data structure module-based approaches [[67], [68], [69], [70]]. The structural comparison and screening based on physiochemical properties, topological indices, molecular graphs, pharmacophore features, molecular shapes, molecular fields, and quantitative measures are expected to reduce false-positive results and yield more effective structures [13,14]. In the current investigation, we were able to shortlist some of the natural products as potential drug-like molecules based on their structural similarities with synthetic chemical drugs. The screening is based on the central foundation of medicinal chemistry that the structurally similar molecules will have similar biological effects [12,14]. The yielded structures were docked to the binding site of the target protein of their respective structurally similar synthetic drugs. To confirm the structural stability, molecular dynamic simulation studies were performed, and the results were compared with unbound and synthetic drug-bound macromolecular structures. The results identified the selected natural products as potential drug leads, and with critical screening, could serve as promising molecules in the first-line treatment for COVID-19 infections. Several studies have also shown the therapeutic potentials of natural products and their interactions with the key viral proteins associated with virulence [9,[71], [72], [73], [74]]. Nevertheless, the future studies comprising in-vitro studies targeting specific proteins followed by their in-silico structure stability assessment with nano and microsecond simulations will validate their use as potential therapeutic molecules.

Ethics approval and consent to participate

Not applicable.

Funding

This work is an extension of a research project supported by the Department of Science and Technology (DST)- Science and Engineering Research Board (), Govt. of India (Grant number: PDF/2018/00237).

Consent for publication

Not applicable.

Availability of data and materials

All the data used during the current study are available from the corresponding author on reasonable request.

CRediT authorship contribution statement

S.J. Aditya Rao: Conceptualization, Investigation, Methodology, Software, Validation, Writing – original draft, Writing – review & editing. Nandini P. Shetty: Formal analysis, Supervision, Writing – review & editing.

Declaration of competing interest

The authors declare that, the above mentioned manuscript has not been published and is not under consideration for publication elsewhere. The authors are aware of the submission and have no conflicts of interest to disclose.